Technical Data Sheet Purified Rat Anti-Mouse CD80

Product Information

553368
B7-1
0.5 mg
0.5 mg/ml
1G10/B7
Activated Mouse 5C2 Cells
Rat IgG2a, ĸ
QC Testing: Mouse
Aqueous buffered solution containing $\leq 0.09\%$ sodium azide.

Description

The 1G10 antibody reacts with CD80 (B7-1). This member of the Ig superfamily, along with CD86 (B7-2), participates in T-cell costimulation *via* interactions with CD28 and CD152 (CTLA-4). CD80 is constitutively expressed on dendritic cells, monocytes, and peritoneal macrophages; and it is inducible on B cells by various means, including activation by LPS, IL-4, and the cross-linking of surface Ig. Expression of CD80 is greatly enhanced on splenic B cells following activation by LPS, with peak expression occurring between 48 and 72 hours. It has been reported that activation of purified B cells with LPS can induce CD80 expression in as few as 18 hours. The 1G10 antibody blocks binding of CTLA-4-Ig to CD80, but it does not block stimulation of T cells by natural antigen-presenting cells. Preliminary evidence has shown that mAb 16-10A1 (Cat. no. 553766) blocks binding of 1G10 mAb to CD80, indicating that the two antibodies may recognize overlapping epitopes on the CD80 molecule. However, the 16-10A1 mAb recognizes an upregulated antigen on UV-irradiated P815 mastocytoma cells which is not detected by the 1G10 mAb; the cause and significance of this differential reactivity of the two anti-CD80 antibodies is unknown.



spenceves (ngh) were standed with public to 1005 mixed (open mixed) and to 1005 mixed public to 1005 mixed public

Preparation and Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at 4°C.

Application Notes

Applic	ation			
T 1				

Flow cytometry	Tested During Development

Recommended Assay Procedure:

Since this antigen is expressed at low density, it may be desirable to amplify staining by using a biotinylated second-step antibody followed by a "bright" third-step reagent, such as Streptavidin-PE (Cat. no. 554061). Other reported applications include blocking of ligand binding.

BD Biosciences

bdbiosciences.com					
United States 877.232.8995	Canada 888.259.0187	Europe 32.53.720.550	Japan 0120.8555.90	Asia Pacific 65.6861.0633	Latin America/Caribbean 55.11.5185.9995
For country-spe	cific contact inf	ormation, visit b	dbiosciences.com	n/how_to_order	/
Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited. For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale. BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2008 BD					

Suggested Companion Products

Catalog Number	Name	Size	Clone
553927	Purified Rat IgG2a, ĸ Isotype Control	0.5 mg	R35-95
554014	Biotin Goat Anti-Rat Ig	0.5 mg	Polyclonal
554061	PE Streptavidin	0.5 mg	(none)

Product Notices

1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.

2. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.

3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

References

Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity. 1995; 2(6):555-559. (Clone-specific: (Co)-stimulation)

Boussiotis VA, Gribben JG, Freeman GJ, Nadler LM. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr Opin Immunol. 1994; 6(5):797-807. (Clone-specific: (Co)-stimulation)

Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med. 1994; 180(2):631-640. (Clone-specific: (Co)-stimulation)

Nabavi N, Freeman GJ, Gault A, Godfrey D, Nadler LM, Glimcher LH. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. *Nature*. 1992; 360(6401):266-268. (Immunogen)

Sojka DK, Donepudi M, Bluestone JA, Mokyr MB. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol. 2000; 164(12):6230-6236. (Biology)

Watts, TH. Personal Communication. . (Biology)